material information disclosure

Corcept Therapeutics faces securities fraud lawsuit for failing to disclose FDA setback on relacorilant drug, causing 50% stock decline.

Law firm files securities fraud lawsuit against BellRing after 52% stock plunge, alleging failure to disclose inventory and supply chain issues.

Securities class action filed against Enphase Energy for allegedly misleading statements on inventory and tax credits. Claim deadline April 2026.

Ultragenyx faces securities lawsuit after failing to disclose setrusumab trial failure, causing 42% stock drop. Investors claim company withheld material information before December announcement.

uniQure faces securities lawsuit over failing to disclose that FDA rejected its gene therapy candidate AMT-130, causing stock to plunge 49%. Lead plaintiff deadline set for April 13, 2026.

BellRing Brands faces securities lawsuit for failing to disclose material information about business challenges between November 2024 and August 2025, leading to significant stock declines.

uniQure stock plummeted 49% after FDA rejected accelerated approval for gene therapy AMT-130, triggering a class action lawsuit alleging securities fraud.

BellRing Brands faces securities fraud lawsuit for allegedly failing to disclose significant inventory issues. Stock fell 52% during the class period amid operational challenges.